MSC1936369B

DRUG2 trials

Sponsors

Merck KGaA, Darmstadt, Germany, Sanofi

Conditions

CancerSolid Tumors

Phase 1

Trial of MSC1936369B in Subjects With Solid Tumors

CompletedNCT00982865

Merck KGaA, Darmstadt, GermanyCancer, Solid Tumors

Start: 2007-12-31End: 2016-04-30Updated: 2018-10-23

Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

CompletedNCT01357330

SanofiSolid Tumors

Start: 2011-05-31End: 2012-06-30Updated: 2016-04-01

Related Papers

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

2021-01-0110 citations

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

2021-01-017 citations